HylaPharm Benefits

Key safety and efficacy advantages include:

  1. Increased drug in tumor due to local injection, enabled by hyaluronan conjugation.
  2. Increased uptake by cancer cells because cancer CD44 binds hyaluronan.
  3. Increased drug into local lymph nodes due to normal lymphatic hyaluronan clearance
  4. Increased drug into local lymph nodes due to drug size in the 20-50 nm lymph node “sweet spot”
  5. Reduced toxicity due to lower overall dose enabled by high tumor penetration
  6. Reduced toxicity due to lower peak blood level at any given dose.

Pet Dog with Squamous Cell Cancer Between Nose and Mouth

Large ulcerated locally advanced squamous cell carcinoma:

Seymour before

Complete response after treatment:

seymour after

 


 

Pet Dog with Squamous Cell Cancer in Mouth

Squamous Cell Cancer

dog1 Large spontaneous squamous cell cancer presenting as exophytic mass on right lower jaw.

1-Week

dog2

Cancer on right lower jaw appears clinically to have significantly receded in 1 week after first HylaPlat injection.

3-Week

dog3

Cancer on right lower jaw appears clinically to have resolved further to the point where a formerly occluded tooth is visible at 3 weeks post first HylaPlat injection. Dog has now received 3 rounds of treatment with no evidence of recurrence after 4 months.

 

Data and photos from Dr. Jeffrey N. Bryan, DVM, MS, PhD, DACVIM (Oncology), Associate Professor of Oncology & Director,
Comparative Oncology Laboratory, College of Veterinary Medicine, University of Missouri.